Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NanoLithium NP03 in Alzheimer's Disease
NCT05423522Phase 2Completed
- Sponsor
- Medesis Pharma
- Start
- May 2022
- Primary completion
- Jan 2024
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of NanoLithium NP03 in Alzheimer's disease (AD), sponsored by Medesis Pharma. Started May 2022; status: completed.
02
Drugs
NanoLithium NP03
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05423522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05423522.